-

CDRH Advisory Meeting Materials Archive

New SearchBack To Search Results
Name of CommitteeNational Mammography Quality Assurance Advisory Committee
Date and TimeThe meeting was held on the following dates:
Apr 19, 04 9:00 AM - 6:00 PM
LocationHoliday Inn, Walker/Whetstone Rooms
Two Montgomery Village Ave.
Gaithersburg , MD
Contact InformationCharles Finder, Center for Devices and Radiological Health (HFZ-240), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-594-3332, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512397. Please call the Information Line for up-to-date information on this meeting.
AgendaThe committee will discuss the following issues:

(1) mechanisms to reduce the regulatory and inspection burden on facilities;

(2) whether mammographic images obtained from reconstructed compressed digital data (lossless or lossy data compression) can be used for primary interpretation or storage;

(3) whether images obtained from digitized film-screen mammograms can be used for primary interpretation or storage; and

(4) revisions to MQSA compliance guidance. The committee will also receive updates on recently approved alternative standards, full field digital mammography accreditation and certification, the inspection demonstration program, the status of MQSA reauthorization, and the new post inspection enforcement strategy.

The MQSA compliance guidance documents, which are in a question and answer format, are available to the public on the Internet at http://www.fda.gov/cdrh/mammography. This guidance is updated continually in response to questions that FDA receives from the public.

ProcedureInterested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by April 5, 2004. Oral presentations from the public will be scheduled between approximately 9:30 a.m. and 10:30 a.m. on April 19, 2004. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before April 5, 2004, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.
 Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.
ConductFDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/oc/advisory/ for procedures on public conduct during advisory committee meetings.
Related Documents
Briefing: Text
Minutes: Text
Transcript: Text
Transcript: PDF Version, Part 1PDF
Transcript: PDF Version, Part 2PDF
Transcript: PDF Version, Part 3PDF
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).
 
-
-
-
-
-